You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 339 Preliminary safety, tolerability and efficacy results of KN026 (a HER2-targeted Bispecific Antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in patients (pts) with HER2 aberrated solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
339 Preliminary safety, tolerability and efficacy results of KN026 (a HER2-targeted Bispecific Antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in patients (pts) with HER2 aberrated solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020187014
Dec 202050014
Jan 202144017
Feb 202134010
Mar 2021134016
Apr 20217607
May 202128024
Jun 20210014
Jul 20210017
Aug 2021007
Sep 20210012
Oct 202142025
Nov 202136018
Dec 20212005
Jan 20224405
Feb 20222007
Mar 20225004
Apr 20227604
May 20224003
Jun 20222204
Jul 20223004
Aug 20223604
Sep 20223202
Oct 20222000
Nov 20222802
Dec 20223204
Jan 20232400
Feb 20232601
Mar 20234001
Apr 20231802
May 20232602
Jun 20231400
Jul 20231403
Aug 20234602
Sep 20232600
Oct 20233606
Nov 20233603
Dec 20233201
Jan 20241600
Feb 20243602
Mar 20242600
Apr 20242001
May 20241400
Jun 20242400
Jul 20243802
Aug 20244202
Sep 20242605
Oct 20244601
Nov 20243004
Dec 20244805
Jan 20251202
Feb 2025605
Mar 2025001
Apr 2025004
May 2025005
Jun 2025106
Total18040309